Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Association between circulating fibroblast growth factor 23, α-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients.

Shibata K, Fujita S, Morita H, Okamoto Y, Sohmiya K, Hoshiga M, Ishizaka N.

PLoS One. 2013 Sep 9;8(9):e73184. doi: 10.1371/journal.pone.0073184. eCollection 2013. Erratum in: PLoS One. 2014;9(4):e93346. PLoS One. 2013;8(10). doi:10.1371/annotation/13086f84-18f2-4ea3-881a-0484b0c411ee.

2.

Association between circulating FGF23, α-Klotho, and left ventricular diastolic dysfunction among patients with preserved ejection fraction.

Okamoto Y, Fujita S, Morita H, Kizawa S, Ito T, Sakane K, Sohmiya K, Hoshiga M, Ishizaka N.

Heart Vessels. 2016 Jan;31(1):66-73. doi: 10.1007/s00380-014-0581-9. Epub 2014 Sep 16.

PMID:
25223536
3.

Association between FGF23, α-Klotho, and Cardiac Abnormalities among Patients with Various Chronic Kidney Disease Stages.

Tanaka S, Fujita S, Kizawa S, Morita H, Ishizaka N.

PLoS One. 2016 Jul 11;11(7):e0156860. doi: 10.1371/journal.pone.0156860. eCollection 2016.

4.

Association of serum levels of FGF23 and α-Klotho with glomerular filtration rate and proteinuria among cardiac patients.

Ozeki M, Fujita S, Kizawa S, Morita H, Sohmiya K, Hoshiga M, Ishizaka N.

BMC Nephrol. 2014 Sep 8;15:147. doi: 10.1186/1471-2369-15-147.

5.

Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease.

Seifert ME, de Las Fuentes L, Ginsberg C, Rothstein M, Dietzen DJ, Cheng SC, Ross W, Windus D, Dávila-Román VG, Hruska KA.

Am J Nephrol. 2014;39(5):392-9. doi: 10.1159/000362251. Epub 2014 May 6.

6.

The relationship of fibroblast growth factors 21 and 23 and α-Klotho with platelet activity measured by platelet volume indices.

Takeda Y, Fujita S, Ikemoto T, Okada Y, Sohmiya K, Hoshiga M, Ishizaka N.

Clin Chem Lab Med. 2015 Sep 1;53(10):1569-74. doi: 10.1515/cclm-2014-1251.

7.

Fibroblast growth factor 23 and soluble klotho in children with chronic kidney disease.

Wan M, Smith C, Shah V, Gullet A, Wells D, Rees L, Shroff R.

Nephrol Dial Transplant. 2013 Jan;28(1):153-61. doi: 10.1093/ndt/gfs411. Epub 2012 Nov 23.

PMID:
23180879
8.

Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.

Pavik I, Jaeger P, Ebner L, Wagner CA, Petzold K, Spichtig D, Poster D, Wüthrich RP, Russmann S, Serra AL.

Nephrol Dial Transplant. 2013 Feb;28(2):352-9. doi: 10.1093/ndt/gfs460. Epub 2012 Nov 4.

9.

Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population.

Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE.

Atherosclerosis. 2009 Dec;207(2):546-51. doi: 10.1016/j.atherosclerosis.2009.05.013. Epub 2009 May 21.

PMID:
19524924
10.

Relationship of FGF23 to indexed left ventricular mass in children with non-dialysis stages of chronic kidney disease.

Sinha MD, Turner C, Booth CJ, Waller S, Rasmussen P, Goldsmith DJ, Simpson JM.

Pediatr Nephrol. 2015 Oct;30(10):1843-52. doi: 10.1007/s00467-015-3125-3. Epub 2015 May 15.

PMID:
25975437
11.

Serum Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated with Low Left Ventricular Ejection Fraction and Elevated Plasma Brain-Type Natriuretic Peptide Level.

Fujita SI, Tanaka S, Maeda D, Morita H, Fujisaka T, Takeda Y, Ito T, Ishizaka N.

PLoS One. 2017 Jan 30;12(1):e0170546. doi: 10.1371/journal.pone.0170546. eCollection 2017.

12.

Fibroblast growth factor 23 and Klotho as cardiovascular risk factors in heart transplant recipients.

Przybylowski P, Wasilewski G, Janik L, Kozlowska S, Nowak E, Malyszko J.

Transplant Proc. 2014 Oct;46(8):2848-51. doi: 10.1016/j.transproceed.2014.09.039.

PMID:
25380933
13.

Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults.

Jovanovich A, Ix JH, Gottdiener J, McFann K, Katz R, Kestenbaum B, de Boer IH, Sarnak M, Shlipak MG, Mukamal KJ, Siscovick D, Chonchol M.

Atherosclerosis. 2013 Nov;231(1):114-9. doi: 10.1016/j.atherosclerosis.2013.09.002. Epub 2013 Sep 13.

14.

Is Serum Uric Acid Independently Associated With Left Ventricular Mass Index, Ejection Fraction, and B-Type Natriuretic Peptide Among Female and Male Cardiac Patients?

Yamauchi Y, Fujita SI, Shibata K, Morita H, Ito T, Sohmiya K, Hoshiga M, Ishizaka N.

Int Heart J. 2017 Aug 3;58(4):562-569. doi: 10.1536/ihj.16-359. Epub 2017 Jul 13.

15.

Gender Specific Association between Serum Fibroblast Growth Factor 23/α-Klotho and Coronary Artery and Aortic Valve Calcification.

Morita H, Takeda Y, Fujita S, Okamoto Y, Sakane K, Teramoto K, Ozeki M, Tasaki R, Kizawa S, Sohmiya K, Hoshiga M, Ishizaka N.

J Atheroscler Thromb. 2015;22(12):1338-46. doi: 10.5551/jat.30635. Epub 2015 Aug 15.

16.

[Mineral metabolism in patients on chronic peritoneal dialysis].

Ceballos O ML, Rojo L A, Azócar P M, Ibacache M MJ, Delucchi B A, Quiroz Z L, Irarrázabal M C, Delgado B I, Ugarte P F, Cano Sch F.

Rev Chil Pediatr. 2014 Feb;85(1):31-9. doi: 10.4067/S0370-41062014000100004. Spanish.

17.

Serum levels of soluble secreted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis.

Shimamura Y, Hamada K, Inoue K, Ogata K, Ishihara M, Kagawa T, Inoue M, Fujimoto S, Ikebe M, Yuasa K, Yamanaka S, Sugiura T, Terada Y.

Clin Exp Nephrol. 2012 Oct;16(5):722-9. doi: 10.1007/s10157-012-0621-7. Epub 2012 Mar 29.

PMID:
22457086
18.

Changes in Serum Concentrations of Fibroblast Growth Factor 23 and Soluble Klotho in Hemodialysis Patients after Total Parathyroidectomy.

Liao SC, Moi SH, Chou FF, Yang CH, Chen JB.

Biomed Res Int. 2016;2016:6453803. doi: 10.1155/2016/6453803. Epub 2016 Nov 24.

19.

Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status.

Carpenter TO, Insogna KL, Zhang JH, Ellis B, Nieman S, Simpson C, Olear E, Gundberg CM.

J Clin Endocrinol Metab. 2010 Nov;95(11):E352-7. doi: 10.1210/jc.2010-0589. Epub 2010 Aug 4.

20.

Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate.

Xie J, Yoon J, An SW, Kuro-o M, Huang CL.

J Am Soc Nephrol. 2015 May;26(5):1150-60. doi: 10.1681/ASN.2014040325. Epub 2014 Dec 4.

Supplemental Content

Support Center